| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -129.3 | -173.2 |
| Net income | -129.3 | -173.4 |
| EPS (diluted, $ a share) | $-0.86 | $-1.64 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: BHVN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Biohaven Ltd.: key numbers
- Share price
- $13.80Close, Nov 16
- Market cap
- $2.08B
- Shares outstanding
- 151.06MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Biohaven Ltd.
All →Biohaven Investor Presentation
Biohaven Ltd. is delivering an investor presentation at the Jefferies Global Healthcare Conference in London from November 16-19, 2026. The presentation provides a corporate update on the company's clinical pipeline, including programs in glutamate modulation, immunology, and oncology.
Biohaven Financial Results
Biohaven Ltd. reported third quarter 2026 financial results and provided updates on its clinical pipeline, including the FDA's acceptance of the NDA resubmission for troriluzole. The company highlighted significant regional licensing deals with SK Biopharmaceuticals and Ono Pharmaceutical, which are expected to provide substantial near-term cash consideration.
“This quarter marked important progress in executing our strategy of building differentiated platforms and partnering them to create both near-term and long-term value. We are excited to have entered into the first ever regional collaboration for an extracellular protein degrader with Ono Pharmaceutical to develop and commercialize our MoDE IgG degrader portfolio, led by BHV-1300, in Japan, South Korea, Taiwan and the ASEAN region.”
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven
“Establishing these unique collaborations with two leading global drug development and commercialization companies is a testament to the impressive potential and versatility of our portfolio.”
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven
Biohaven Business Update
Biohaven announced that the FDA has accepted its New Drug Application (NDA) resubmission for Vyglxia (troriluzole) for the treatment of spinocerebellar ataxia (SCA). The FDA has assigned a user fee goal date in the first quarter of 2027 and plans to convene an advisory committee meeting to review the application.
- Counterparty
- FDA
Biohaven Licensing Deal with Ono Pharmaceutical Co., Ltd. Worth $100M
Biohaven granted Ono Pharmaceutical an exclusive license to develop and commercialize its MoDE pan IgG degrader portfolio, including lead candidate BHV-1300, in Japan, South Korea, Taiwan, and ASEAN countries. Biohaven receives an $80 million upfront payment and is eligible for a $20 million milestone payment plus royalties of approximately 20% on net sales in the territory.
- Value
- $100M
- Counterparty
- Ono Pharmaceutical Co., Ltd.